BR112012023660B8 - uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancer - Google Patents
uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancerInfo
- Publication number
- BR112012023660B8 BR112012023660B8 BR112012023660A BR112012023660A BR112012023660B8 BR 112012023660 B8 BR112012023660 B8 BR 112012023660B8 BR 112012023660 A BR112012023660 A BR 112012023660A BR 112012023660 A BR112012023660 A BR 112012023660A BR 112012023660 B8 BR112012023660 B8 BR 112012023660B8
- Authority
- BR
- Brazil
- Prior art keywords
- naphthofuran
- compounds
- treatment
- prodrug
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
novos métodos para direcionar células-tronco cancerosas a invenção fornece compostos de naftofurano, polimorfos de compostos de naftogurano, compostos de naftofurano na forma de partículas, as composições purificadas que contêm um ou mais compostos de naftofurano, as composições purificadas que contêm um ou mais compostos de naftofurano em forma de partículas, os métodos de produção destes compostos, polimorfos, composições purificadas e/ou formas de partículas de naftofurano, e os métodos de uso destes compostos, polimorfos, composições purificadas e/ou formas de partículas de naftofurano para o tratamento de sujeitos com necessidade dos mesmos.novel methods for targeting cancer stem cells the invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particulate form, purified compositions containing one or more naphthofuran compounds, purified compositions containing one or more compounds of naphthofuran in particulate form, the methods of production of these compounds, polymorphs, purified compositions and/or particulate forms of naphthofuran, and the methods of using these compounds, polymorphs, purified compositions and/or particulate forms of naphthofuran for treatment of subjects in need of them.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31588610P | 2010-03-19 | 2010-03-19 | |
US31589010P | 2010-03-19 | 2010-03-19 | |
US61/315,890 | 2010-03-19 | ||
US61/315,886 | 2010-03-19 | ||
US32581410P | 2010-04-19 | 2010-04-19 | |
US61/325,814 | 2010-04-19 | ||
PCT/US2011/029283 WO2011116399A1 (en) | 2010-03-19 | 2011-03-21 | Novel methods for targeting cancer stem cells |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012023660A2 BR112012023660A2 (en) | 2015-09-15 |
BR112012023660B1 BR112012023660B1 (en) | 2021-05-18 |
BR112012023660B8 true BR112012023660B8 (en) | 2021-05-25 |
Family
ID=47678420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012023660A BR112012023660B8 (en) | 2010-03-19 | 2011-03-21 | uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancer |
Country Status (9)
Country | Link |
---|---|
US (2) | US9730909B2 (en) |
EP (1) | EP2547205B1 (en) |
JP (1) | JP2013522326A (en) |
CN (1) | CN103025159A (en) |
AU (1) | AU2011227023B2 (en) |
BR (1) | BR112012023660B8 (en) |
CA (2) | CA2793527A1 (en) |
RU (1) | RU2591823C2 (en) |
WO (1) | WO2011116399A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2569215T3 (en) | 2007-09-10 | 2016-05-09 | Boston Biomedical, Inc. | A new group of inhibitors of the Stat3 pathway and inhibitors of the cancer stem cell pathway |
CN107721958A (en) * | 2010-03-19 | 2018-02-23 | 北京强新生物科技有限公司 | The new compound and composition of target on cancer stem cell |
BR112015025347A2 (en) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment |
CN106163284A (en) | 2014-02-07 | 2016-11-23 | 北京强新生物科技有限公司 | 3 substituted carbonyl naphtho-[2,3 b] furan derivatives or its pharmaceutically acceptable salts |
DK3153508T3 (en) | 2014-06-09 | 2020-05-18 | Kyoto Pharma Ind | NAPHTHOFURAND DERIVATIVES FOR USE AS ANTICANCER AGENTS |
AU2016249157A1 (en) | 2015-04-17 | 2017-11-02 | Boston Biomedical, Inc. | Methods for treating cancer |
TW201713327A (en) | 2015-04-17 | 2017-04-16 | 波士頓生醫公司 | Methods for treating cancer |
CA2988126A1 (en) * | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
CN109069469A (en) | 2016-01-20 | 2018-12-21 | 北京强新生物科技有限公司 | The method for the treatment of cancer |
CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
US10926226B2 (en) * | 2018-03-08 | 2021-02-23 | ExxonMobil Research & Engineering Company Company | Functionalized membranes and methods of production thereof |
KR20210076951A (en) | 2018-10-12 | 2021-06-24 | 1글로브 바이오메디칼 씨오., 엘티디. | Novel Combination Approaches to Treat Chemotherapy Refractory Cancer |
CN111825644B (en) * | 2019-04-18 | 2023-07-28 | 中国医学科学院药物研究所 | 2, 3-dihydronaphtho [2,3-b ] furan-4, 9-diketone compound and preparation method and application thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0402192A1 (en) | 1989-05-31 | 1990-12-12 | BODET, Jean Augustin | Article made of carton or similar material and method for its manufacture |
JPH04139177A (en) | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | Furalbenzoquinone derivative, its production and carcinostatic agent |
JPH1121284A (en) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | Furanonaphthoquinone derivative and medicine containing the same |
US6174913B1 (en) | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
AU2736400A (en) | 1999-01-27 | 2000-08-18 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
MXPA02000828A (en) | 1999-08-02 | 2002-07-30 | Hoffmann La Roche | Retinoids for the treatment of emphysema. |
JP2001097860A (en) * | 1999-09-29 | 2001-04-10 | Japan Science & Technology Corp | Anti-drug-resistant bacterium agent and anti-chlamydia agent |
UA75055C2 (en) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
AU2002307217A1 (en) | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
GB0117696D0 (en) * | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
US20040092428A1 (en) | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
CN1310652C (en) * | 2001-11-29 | 2007-04-18 | 特拉科斯有限公司 | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
JP2005526084A (en) | 2002-03-15 | 2005-09-02 | ナットイムネ・アクティーゼルスカブ | Pharmaceutical composition comprising mannose-binding lectin |
WO2004026253A2 (en) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
AR042052A1 (en) | 2002-11-15 | 2005-06-08 | Vertex Pharma | USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES |
IS6633A (en) | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Compositions of finasteride tablets |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US20050049207A1 (en) | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
WO2005033048A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Wnt pathway antagonists |
WO2005058829A1 (en) | 2003-12-11 | 2005-06-30 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
CA2563305A1 (en) | 2004-04-09 | 2005-11-24 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
JP2004224802A (en) | 2004-04-21 | 2004-08-12 | Japan Science & Technology Agency | Antibacterial agent |
CN101106983A (en) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | Combinations comprising JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
CA2599393A1 (en) | 2005-02-25 | 2006-08-31 | The Regents Of The University Of Michigan | Small molecule inhibitors of stat3 and the uses thereof |
JP2006248978A (en) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
CN101142202A (en) * | 2005-03-16 | 2008-03-12 | 太日保日本株式会社 | Anticancer compound, intermediate therefor, and processes for producing these |
JP2006290871A (en) | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | Compound exhibiting anti-cancer property, intermediate therefor and method for producing the same |
US20060252073A1 (en) | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
US20070243192A1 (en) | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
EP2007714A2 (en) | 2006-03-31 | 2008-12-31 | The Board of Regents of The University of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
US20070238770A1 (en) | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
JP4077863B1 (en) | 2007-05-31 | 2008-04-23 | タヒボジャパン株式会社 | Process for producing optically active 2- (1-hydroxyethyl) -5-hydroxynaphtho [2,3-b] furan-4,9-dione having anticancer activity |
ES2569215T3 (en) * | 2007-09-10 | 2016-05-09 | Boston Biomedical, Inc. | A new group of inhibitors of the Stat3 pathway and inhibitors of the cancer stem cell pathway |
WO2009060282A2 (en) | 2007-11-06 | 2009-05-14 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
CN107721958A (en) * | 2010-03-19 | 2018-02-23 | 北京强新生物科技有限公司 | The new compound and composition of target on cancer stem cell |
-
2011
- 2011-03-21 RU RU2012144420/15A patent/RU2591823C2/en active
- 2011-03-21 JP JP2013500247A patent/JP2013522326A/en active Pending
- 2011-03-21 EP EP11757135.6A patent/EP2547205B1/en active Active
- 2011-03-21 CA CA2793527A patent/CA2793527A1/en not_active Abandoned
- 2011-03-21 BR BR112012023660A patent/BR112012023660B8/en active IP Right Grant
- 2011-03-21 US US13/634,694 patent/US9730909B2/en active Active
- 2011-03-21 CN CN2011800233152A patent/CN103025159A/en active Pending
- 2011-03-21 WO PCT/US2011/029283 patent/WO2011116399A1/en active Application Filing
- 2011-03-21 CA CA2946890A patent/CA2946890A1/en not_active Abandoned
- 2011-03-21 AU AU2011227023A patent/AU2011227023B2/en active Active
-
2017
- 2017-07-05 US US15/642,105 patent/US20170319537A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2591823C2 (en) | 2016-07-20 |
CA2946890A1 (en) | 2011-09-22 |
US20130028944A1 (en) | 2013-01-31 |
JP2013522326A (en) | 2013-06-13 |
US9730909B2 (en) | 2017-08-15 |
AU2011227023A1 (en) | 2012-09-27 |
US20170319537A1 (en) | 2017-11-09 |
AU2011227023B2 (en) | 2015-05-28 |
CA2793527A1 (en) | 2011-09-22 |
EP2547205A1 (en) | 2013-01-23 |
EP2547205B1 (en) | 2024-03-20 |
EP2547205A4 (en) | 2013-08-14 |
RU2012144420A (en) | 2014-04-27 |
CN103025159A (en) | 2013-04-03 |
BR112012023660A2 (en) | 2015-09-15 |
WO2011116399A1 (en) | 2011-09-22 |
BR112012023660B1 (en) | 2021-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012023660B8 (en) | uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancer | |
GT201400111A (en) | SUBSTITUTED TRIAZOLOPIRIDINS | |
CL2012002319A1 (en) | Compounds derived from amino-thienopyrimidines containing a substituted alkyl group, mnk inhibitors | or mnk2; pharmaceutical composition; and its use for the prophylaxis or therapy of metabolic diseases, hematopoietic disorders, neurodegenerative diseases, cancer, among others. | |
EA201690752A1 (en) | INHIBITORS G12C KRAS | |
BR112015009942A2 (en) | tricyclic fused thiophene derivatives as jak inhibitors | |
IL232267A (en) | (4-phenylimidazol-2 -yl) ethylamine derivatives, pharmaceutical compositions containing same and uses thereof in the treatment of diseases for which inhibition of the nav1.8 sodium channel is indicated | |
UY33246A (en) | TIENOPIRIMIDINES CONTAINING CYCLLOQUAL FOR PHARMACEUTICAL COMPOSITIONS | |
UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
BR112015011456A2 (en) | aminopyrimidine compounds as t790m-containing mutant egfr inhibitors | |
MX345928B (en) | Therapeutically active compositions and their methods of use. | |
CO7111284A2 (en) | Uracil Spirooxetane Nucleosides | |
BR112015009216A2 (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a pharmaceutical composition | |
UY33241A (en) | ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?. | |
CL2015001279A1 (en) | Compounds derived from pyridine, urate transporter inhibitors urat 1; pharmaceutical composition that includes them; use for the treatment or prevention of diseases such as gout, hyperuricemia, hypertension, kidney diseases, among others. | |
EA201491356A1 (en) | PROTEINKINAZ INHIBITORS (OPTIONS), THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS | |
EA201500365A1 (en) | COMBINATION OF REGORAPHENIBE AND ACETYLSALICYLIC ACID TO CURE CANCER | |
CR20150114A (en) | COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB | |
BR112015018168A2 (en) | soft rock inhibitors | |
EA201500298A1 (en) | ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES | |
BR112013001632A2 (en) | compound, pharmaceutical composition, method of inhibiting a jak kinase activity in vitro, use of a compound, or pharmaceutical composition, and method of making a compound | |
EA201600337A1 (en) | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
DOP2015000170A (en) | CHEMICAL COMPOUNDS | |
BR112015020139A2 (en) | therapeutic compounds and their uses | |
WO2013040227A3 (en) | Therapeutic compounds | |
CR20130693A (en) | TYPICAL ORTALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/16 , A61K 31/35 Ipc: A61K 31/35 (2006.01), A61K 31/27 (2006.01), A61K 3 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |